Letter to the editor: The efficacy and safety of VEGF/VEGFR inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma. Li D, Li C, Shi S. Oral Oncol 2023;145:106497.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Li D, Li C, Shi S. Letter to the editor: The efficacy and safety of VEGF/VEGFR inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol 2023;145:106497.
PMID: 37453165